CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for ...
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site. Posimir ® (bupivacaine solution) is now available for ...
Please provide your email address to receive an email when new articles are posted on . Durect Corporation has announced the FDA approval of Posimir, a post-surgical, non-opioid local analgesic for ...
Please provide your email address to receive an email when new articles are posted on . Subacromial decompression with arthroscopic rotator cuff repair yielded a 21% risk reduction for revision ...
Arthroscopic subacromial decompression surgery does not reduce pain any more than arthroscopy alone in people with shoulder impingement, researchers say. "[T]he findings from our study suggest that ...
POSIMIR ® (bupivacaine solution) for infiltration use reduced mean pain over 72 hours after arthroscopic subacromial decompression surgery compared with vehicle control and improved several measures ...
POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million ...
Correspondence to Dr Mikkel Bek Clausen, Department of Midwifery, Physiotherapy, Occupational Therapy and Psychomotor Therapy, Faculty of Health, University College Copenhagen, Copenhagen, Denmark; ...
Rates of serious complications associated with shoulder surgery are low, but one in 26 patients need further surgery within a year, finds a study in The BMJ today. The use of keyhole (arthroscopic) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback